Materials • Major Chemicals
$17.27 ▲ +0.02
(+0.12%)
MKT CAP: $462.1M • VOL: 1.52M
52W L $11 52W H $19
LXFR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $384.6M | $391.9M | $405.0M |
| YoY Revenue Growth % | -1.9% | -3.2% | — |
| Gross Profit | $89.2M | $85.7M | — |
| Gross Margin % | 23.2% | 21.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $24.0M | $30.1M | $4.2M |
| Operating Margin % | 6.2% | 7.7% | 1.0% |
| Net Income (GAAP) | $7.7M | $18.4M | -$1.9M |
| EBITDA (Normalized) | $30.2M | $38.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $34.0M | $51.1M | $26.3M |
| Capital Expenditures (CapEx) | $7.8M | $10.3M | — |
| Free Cash Flow (FCF) | $26.2M | $40.8M | $26.3M |
| FCF Margin % | 6.8% | 10.4% | 6.5% |
| Return on Invested Capital (ROIC %) | 8.2% | 9.2% | — |
| Cash & Short-Term Equivalents | $8.3M | $4.1M | — |
| Total Debt (Short + Long Term) | $14.4M | $42.0M | — |
| Total Stockholders' Equity | $226.4M | $219.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LXFR.